Roche Holding Ltd CAD Hedged CIBC CDR (ROG) Stock Price & Analysis

2 Followers

ROG Stock Chart & Stats

CA$31.71-CA$0.29(-0.91%)

At close: Nov 12 4:00 PM EST

Day’s Range: CAD 31.71 - CAD 32.23
52-Week Range: CAD 22.54 - CAD 32.24
Previous Close: CAD 32.00
Volume: N/A
Average Volume (3M): 2,946
Market Cap: CAD 548.85B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 26.2
Beta: 0.83
Next Earnings: Jan 28, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Mar 13, 2026
Dividend Yield: 1.56%

Roche Holding Ltd CAD Hedged CIBC CDR News

Roche price target raised to CHF 440 from CHF 400 at Citi

Citi raised the firm’s price target on Roche (RHHBY) to CHF 440 from CHF 400 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

3d agoCHRO ROP

Roche says FDA clears new cobas eplex RP3 panel

Roche (RHHBY) announced the U.S. FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3. Designed for the automated cobas eplex system, this flexible syndromic test offers up to

1w agoCHRO ROP

Roche downgraded to Neutral from Buy at UBS

UBS analyst Matthew Weston downgraded Roche (RHHBY) to Neutral from Buy with a price target of CHF 420, up from CHF 376. The firm cites valuation following the stock’s recent

1w agoCHRO ROP

Roche receives CE Mark for cobas smart e immunoanalyser

Roche (RHHBY) announced that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of

2w agoCHRO ROP

Weekend Fly By: Top five stock stories

Get caught up quickly on the top news from the weekend this five Top Five list. Volkswagen’s (VWAGY) Audi announced plans to establish its first U.S. production site in Georgia.

2w agoAMRN CHRO

Genentech says Phase III Krascendo 1 study met primary, secondary endpoints

Genentech, a member of the Roche (RHHBY) Group, announced results from the Phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor,

2w agoCHRO ROP

Zymeworks price target raised to $52 from $50 at Jefferies

Jefferies raised the firm’s price target on Zymeworks (ZYME) to $52 from $50 and keeps a Buy rating on the shares. The company and Roche (RHHBY) entered into an exclusive

2w agoCHRO ZYME

Roche says Sefaxersen trial shows meaningful reduction in proteinuria

Ionis Pharmaceuticals (IONS) partner Roche (RHHBY) announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating

2w agoCHRO IONS

Roche reports Sefaxersen achieved 43.1% reduction in proteinuria in trial

Roche (RHHBY) announced late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy receiving optimized standard of care, demonstrating that investigational sefaxersen achieved

2w agoCHRO ROP

Zymeworks signs collaboration and license agreement with Roche for ZW209

Zymeworks (ZYME) announced that it has entered into a global license and collaboration agreement with Roche (RHHBY) for the research, development and commercialization of ZW209, a T cell engager targeting

2w agoCHRO ZYME

Analyst Reiterates Buy on Roche, Maintains CHF 395 Price Target on Underappreciated Long-Term Pipeline Upside

Analyst Justin Smith of Bernstein assigned a Buy rating on Roche Holding AG, retaining the price target of CHF395.00. Justin Smith has given his Buy rating due to a combination

6M agoCHRO ROP

Roche: Fenebrutinib Safety Concerns Skew Risk‑Reward, Driving Sell Rating

Analyst Sarita Kapila of Morgan Stanley maintained a Sell rating on Roche Holding AG, retaining the price target of CHF295.00. Sarita Kapila has given his Sell rating due to a

8M agoCHRO ROG

Roche: Clinical Momentum Improves Outlook but Valuation Keeps Risk/Reward Balanced at Hold

In a report released yesterday, James Quigley from Goldman Sachs upgraded Roche Holding AG to a Hold, with a price target of CHF365.00. James Quigley has given his Hold rating

10M agoCHRO ROG

ROG FAQ

What was Roche Holding Ltd CAD Hedged CIBC CDR’s price range in the past 12 months?

Roche Holding Ltd CAD Hedged CIBC CDR lowest stock price was C$22.54 and its highest was C$32.24 in the past 12 months.

What is Roche Holding Ltd CAD Hedged CIBC CDR’s market cap?

Roche Holding Ltd CAD Hedged CIBC CDR’s market cap is C$548.85B.

When is Roche Holding Ltd CAD Hedged CIBC CDR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Roche Holding Ltd CAD Hedged CIBC CDR overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Roche Holding Ltd CAD Hedged CIBC CDR pay dividends?

Roche Holding Ltd CAD Hedged CIBC CDR pays a dividend of C$0.499 which represents an annual dividend yield of 1.56%. See more information on Roche Holding Ltd CAD Hedged CIBC CDR dividends here

What is Roche Holding Ltd CAD Hedged CIBC CDR’s EPS estimate?

Roche Holding Ltd CAD Hedged CIBC CDR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Roche Holding Ltd CAD Hedged CIBC CDR have?

Roche Holding Ltd CAD Hedged CIBC CDR has 702,562,700 shares outstanding.

Which hedge fund is a major shareholder of Roche Holding Ltd CAD Hedged CIBC CDR?

Currently, no hedge funds are holding shares in TSE:ROG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Roche Holding Ltd CAD Hedged CIBC CDR

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding Ltd CAD Hedged CIBC CDR (ROG) Earnings & Revenues

Historic Earnings Reports

ROG Earnings Call

Q2 2026

Earnings Call SentimentPositive

The call conveyed strong confidence in Roche's operating performance, with broad sales growth, 10% core operating profit growth, expanding margins, strong cash flow, significant regulatory progress, and extensive late-stage pipeline momentum. The company also confirmed its full-year outlook and highlighted multiple growth platforms across Pharma and Diagnostics. Offsetting issues included foreign exchange pressure, China's pricing reform, a weak respiratory season, loss-of-exclusivity effects, competitive pressure on selected products, and a higher expected second-half tax rate. Overall, the positive financial, operational, and pipeline developments significantly outweighed the stated challenges.

View all TSE:ROG earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	5	2
Technical Analysis	3	5	2
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to TSE:ROG
Company	Price & Change	Follow
TSE:BHCBausch Health Companies
TSE:NVSNovartis AG CAD Hedged CIBC CDR

Compare TSE:ROG Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

ROG Stock Chart & Stats

Roche Holding Ltd CAD Hedged CIBC CDR News

Roche price target raised to CHF 440 from CHF 400 at Citi

Roche says FDA clears new cobas eplex RP3 panel

Roche downgraded to Neutral from Buy at UBS

Roche receives CE Mark for cobas smart e immunoanalyser

Weekend Fly By: Top five stock stories

Genentech says Phase III Krascendo 1 study met primary, secondary endpoints

Zymeworks price target raised to $52 from $50 at Jefferies

Roche says Sefaxersen trial shows meaningful reduction in proteinuria

Roche reports Sefaxersen achieved 43.1% reduction in proteinuria in trial

Zymeworks signs collaboration and license agreement with Roche for ZW209

Analyst Reiterates Buy on Roche, Maintains CHF 395 Price Target on Underappreciated Long-Term Pipeline Upside

Roche: Fenebrutinib Safety Concerns Skew Risk‑Reward, Driving Sell Rating

Roche: Clinical Momentum Improves Outlook but Valuation Keeps Risk/Reward Balanced at Hold

ROG FAQ

Company Description

Roche Holding Ltd CAD Hedged CIBC CDR

Roche Holding Ltd CAD Hedged CIBC CDR (ROG) Earnings & Revenues

ROG Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive